

## Literatura ACTA MEDICINAE 11/2017 Farmakologická léčba

- 2 **Tyrosinkinázové inhibitory v léčbě solidních nádorů**  
PharmDr. Šárka Kozáková, MBA Masarykův onkologický ústav, Brno
- 2 **Atezolizumab**  
doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU Brno, Oddělení klinických hodnocení MOÚ, Brno  
MUDr. Renata Hejnová Oddělení klinických hodnocení MOÚ, Brno
- 2 **Novinka v léčbě metastatického kolorektálního karcinomu**  
MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně
- 3 **Bezpečnostní profil ibrutinibu a idelalisibu**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 3 **Podkožní forma rituximabu – starý a přesto nový lék: co přináší z pohledu lékaře, zdravotní sestry a pacienta v běžné klinické praxi**  
doc. MUDr. Andrea Janíková, Ph.D. | Jana Charouzková Interní hematologická a onkologická klinika FN a LF MU, Brno
- 3 **Interakce léčiv prodlužujících QT interval**  
Mgr. Olga Svobodová Oddělení klinické farmacie – Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno  
PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie – Lékárna, FN Ostrava  
doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU, Brno
- 3 **Fixní kombinace perindoprilu argininu s amlodipinem**  
prof. MUDr. Jiří Widimský, CSc. Jr. III. interní klinika – Centrum pro hypertenzi VFN a 1. LF UK, Praha
- 4 **Inhibice systému RAAS perindoprilem ve vztahu k dysfunkci endotelu: studie PERTINENT**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 4 **Fixní kombinace candesartanu s amlodipinem**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 4 **Intervence kardiovaskulárního rizika, proč vítězíme a selháváme**
- 5 **Perindopril erbumin prověřen klinickými studiemi**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Porovnání klinického efektu Warfarinu PMCS vůči Warfarinu Orion**  
MUDr. Petr Magrot OKB Lab, a. s., Ústí nad Labem Leona Hrdličková, DiS. SVZŠ, Ústí nad Labem
- 5 **Léčba bolesti v těhotenství s ohledem na změnu farmakokinetiky těhotných**  
PharmDr. Eliška Vaculíková Nemocniční lékárna, Pracoviště klinického farmaceuta Nemocnice s poliklinikou Havířov  
Mgr. Olga Svobodová Oddělení klinické farmacie – Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno  
MUDr. Jan Malaník Gynekologicko-porodní oddělení Slezské nemocnice Opava
- 6 **Tapentadol v léčbě chronické nenádorové bolesti – kazuistika**  
MUDr. Lenka Klimešová ARIM, Nemocnice Milosrdných bratří, Brno
- 6 **Nová možnost léčby revmatoidní artritidy – Olumiant**  
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 6 **Secukinumab v léčbě pacientky se závažným průběhem psoriázy a psoriatické artritidy – kazuistika**  
MUDr. Martina Kojanová, Ph.D. | MUDr. Jorga Fialová Dermatovenerologická klinika 1. LF UK a VFN, Praha  
MUDr. Liliana Šedová Revmatologický ústav, Praha, Revmatologická klinika 1. LF UK, Praha
- 6 **Fixní kombinace azelastinu a fluticason propionátu – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 7 **Současný pohled na léčbu idiopatické plicní fibrózy**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Fosfomycin trometamol – od laboratorního ověření účinnosti k urologické praxi**  
MUDr. Miroslav Louda, Ph.D. Urologická klinika FN a LF UK, Hradec Králové  
MUDr. Miroslav Fajfr, Ph.D. Ústav klinické mikrobiologie, FN Hradec Králové
- 7 **Farmakologická léčba benigní hyperplazie v současnosti**  
MUDr. Jiří Klečka, Ph.D., MBA Urocentrum Plzeň a Urologická klinika FN Královské Vinohrady a 3. LF UK, Praha
- 7 **Význam perorální léčby roztroušené sklerózy v první linii**  
prof. MUDr. Jan Mareš, Ph.D. Neurologická klinika LF UP a FN Olomouc

# Tyrosinkinázové inhibitory v léčbě solidních nádorů

PharmDr. Šárka Kozáková, MBA Masarykův onkologický ústav, Brno

- 1 Gunby, R. H. – Sala, E. – Tartari, C. J., et al.: Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. *Anticancer Agents Med Chem*, 2007, 77, s. 594–611, doi:10.2174/18715200778411340.
- 2 Wang, S. C. – Hung, M. C.: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. *Clin Cancer Res*, 2009, 15, s. 6484–6489.
- 3 Nagaria, N. C. – Cogswell, J. – Choe, J. K., et al.: Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. *J Clin Oncol*, 2005, 23, s. 2423–2424.
- 4 Bunn, P. A. – Kelly, K.: New combination in the treatment of lung cancer. A time for optimism. *Chest*, 2000, 117, s. 1385–1435.
- 5 Krákorová, G. – Svatoň, M.: Afatinib – nový ireverzibilní tyrosinkinázový inhibitor v klinické praxi. *Remedia*, 2014, 24, s. 130–135.
- 6 Solca, F. – Meyer, R.: Inactivation of the EGR signaling pathway by BIBW 2992. A time course analysis. 28-02, 30. 11. 2002.
- 7 Bláček, J.: Tagrisso (osimertinib, AZD9291). Nové léky 2015/2016. Dostupné z: <http://www.noveleky.cz/index.php/onkologie/36-tagrisso-osimertinib-azd9291>, vyhledáno 4. 10. 2017.
- 8 Petráková, K. – Demlová, R.: Lapatinib. *Remedia*, 2008, 18, s. 13–18.
- 9 Kadlec, B. – Skříčková, J.: Ceritinib v léčbě nemalobuněčného karcinomu plic. *Remedia*, 2016, 26, s. 29–32.
- 10 Maillet, D. – Martel Lafay, I. – Arpin, D., et al.: Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4 ALK rearrangement. *J Thorac Oncol*, 2013, 8, s. e30–e31.
- 11 Doebele, R. C. – Pilling, A. B. – Aisner, D. L., et al.: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res*, 2012, 18, s. 1472–1482.
- 12 Mok, T. – Spigel, D. – Felip, E., et al.: ASCEND 2: A single arm, open label, multicenter Phase II study of ceritinib in adult patients (pts) with ALK rearranged (ALK+) non small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Abstrakt 8059. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA.
- 13 Steeghs, N. – Nortier, J. W. – Gelderblom, H.: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. *Ann Surg Oncol*, 2007, 14, s. 942–953.
- 14 Carmeliet, P. – Jain, R. K.: Angiogenesis in cancer and other diseases. *Nature*, 2000, 407, s. 249–257.
- 15 Chow, L. Q. – Eckhardt, G.: Sunitinib: from rational design to clinical efficacy. *J Clin Oncol*, 2007, 25, s. 2858–2859.
- 16 Gibbons, J. J. – Discifani, C. – Peterson, R.: The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo (abstract 1000). *Proc Am Assoc Cancer Res*, 1999, 40, s. 301–304.
- 17 Deeks, E. D. – Keating, G. M.: Sunitinib. *Drugs*, 2006, 66, s. 2255–2266; diskuze s. 2267–2268.
- 18 Wells, S. A. – Gosnell, J. E. – Gagel, R. F., et al.: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Oncol*, 2010, 28, s. 767–772.
- 19 Reck, M. – Kaiser, R. – Mellemegaard, A., et al.: LUME-Lung 1 study group: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155.
- 20 Wilhelm, S. M. – Carter, C. – Tang, L., et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res*, 2004, 64, s. 7099–7109.
- 21 Choueiri, T. K. – Escudier, B. – Powles, T., et al.: Cabozantinib versus everolimus in advanced renal cell carcinoma. *N Engl J Med*, 2015, 373, s. 1814–1823.
- 22 Rini, B. I. – Rixe, O. – Bukowski, R. M., et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). *J Clin Oncol*, 2005, 23, abstrakt 4509.
- 23 Vitásková, D. – Melichar, B.: Axitinib v léčbě metastatického karcinomu ledviny. *Remedia*, 2012, 22, s. 442–444.
- 24 Cabanillas, M. E. – Habra, M. A.: Lenvatinib: role in thyroid cancer and other solid tumors. *Cancer Treat Rev*, 2016, 42, s. 47–55.
- 25 Stjepanovic, N. – Capdevila, J.: Multikinase inhibitors in the treatment of thyroid cancer. Specific role of lenvatinib. *Biologics*, 2014, 8, s. 129–139.
- 26 Gotink, K. J. – Verheul, H. M. W.: Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? *Angiogenesis*, 2010, 13, s. 1–14.
- 27 Obermanová, R., et al.: Regorafenib v léčbě kolorektálního karcinomu. Studie CORRECT a vlastní zkušenosti s léčbou regorafenibem v Masarykově onkologickém ústavu. *Remedia*, 2014, 24, s. 419–424.

## Atezolizumab

doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU Brno, Oddělení klinických hodnocení MOÚ, Brno MUDr. Renata Hejnová Oddělení klinických hodnocení MOÚ, Brno

- 1 Chen, L.: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. *Nat Rev Immunol*, 2004, 4, s. 336–347.
- 2 Taube, J. M.: Colocalization of inflammatory response with B7-1 expression in human melanocytic lesion supports an adaptive resistance mechanism of immune escape. *Sci Transl Med*, 2012, 4, 127ra37.
- 3 Keir, M. E. – Butte, M. J. – Freeman, J., et al.: PD-1 and its ligands in tolerance and immunity. *J Annu Rev Immunol*, 2008, 26, s. 677–704.
- 4 Dong, H. – Strome, S. E. – Salomao, D. R., et al.: Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*, 2002, 8, s. 793–800.
- 5 Curiel, T. J. – Wei, S. – Dong, H., et al.: Blockade of B7-1 improves myeloid dendritic cell-mediated antitumor immunity. *Nat Med*, 2003, 9, s. 562–567.
- 6 Patsoukis, N. – Sari, D. – Boussiotis, V. A.: PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. *Cell Cycle*, 2012, 11, s. 4305–4309.
- 7 Patsoukis, N. – Bardhan, K. – Chatterjee, P., et al.: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nat Commun*, 2015, 6, s. 6692.
- 8 Staron, M. M. – Gray, S. M. – Marshall, D., et al.: The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection. *Immunity*, 2014, 41, s. 802–814.
- 9 Chinai, J. M. – Janakiram, M. – Chen, F., et al.: New immunotherapies targeting the PD-1 pathway. *Trends Pharmacol Sci*, 2015, 36, s. 587–595.
- 10 Barlesi, F., et al.: Primary analysis from OAK, a randomized Phase III study comparing atezolizumab with docetaxel in advanced NSCLC. Prezentováno na setkání European Society for Medical Oncology, Kodaň, Dánsko, říjen 2016.
- 11 Spira, A., et al.: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs. docetaxel in 2L/3L NSCLC (POPLAR). Prezentováno na setkání American Society of Clinical Oncology, Chicago, USA, květen 2015.
- 12 Fehrenbacher, L. – Spira, A. – Ballinger, M., et al.: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*, 2016, 387, s. 1837–1846.
- 13 Bielek, O. – Bohovicova, L. – Demlova, R., et al.: Non-small cell lung cancer – from immunobiology to immunotherapy. *Klin Onkol*, 2016, 29, suppl. 4, s. 78–87.
- 14 Powles, T.: IMvigor 211: A phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Prezentováno na druhé specializované konferenci European Association for Cancer Research (EACR), American Association for Cancer Research (AACR) a Italian Cancer Society (SIC), Florencie, Itálie, 2017.
- 15 Rosenberg, J., et al.: Atezolizumab in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). Prezentováno na European Cancer Congress, Vídeň, Rakousko, září 2015.
- 16 Lakomy, R. – Poprach, A.: Side-effects of modern immunotherapy and how to solve them in the clinics. *Klin Onkol*, 2015, 28, suppl. 4, s. 45103–114.
- 17 Demlova, R. – Valik, D. – Obermannova, R., et al.: The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-check point inhibitors. *Physiol Res*, 2016, 65, suppl. 4, s. 455–462.
- 18 [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## Novinka v léčbě metastatického kolorektálního karcinomu

MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně

- 1 Dostupné z: [www.svod.cz](http://www.svod.cz).
- 2 National Comprehensive Cancer Network. NCCN guidelines for colon cancer (version 1.2017). 2017. Dostupné z: [http://www.nccn.org/professionals/physician\\_gls\\_f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls_f_guidelines.asp), vyhledáno 4. 12. 2017.
- 3 Emura, T. – Murakami, Y. – Nakagawa, F., et al.: A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. *Int J Mol Med*, 2004, 13, s. 545–549.
- 4 Hong, D. S. – Abbruzzese, J. L. – Bogaard, K., et al.: Phase I study to determine the safety and pharmacokinetics of oral administrativ of TAS-102 in patients with solid tumors. *Cancer*, 2006, 107, s. 1383–1390.
- 5 Overman, M. J. – Varadhachary, G. – Kopetz, S., et al.: Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. *Invest New Drugs*, 2008, 26, s. 445–454.
- 6 Green, M. C. – Pusztai, L. – Theriault, L. R., et al.: Phase I study to determine the safety of oral administrativ of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). *Proc Am Soc Clin Oncol*, 2006, 24, abstrakt 10576.
- 7 Doi, T. – Ohtsu, A. – Yoshino, T., et al.: Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. *Br J Cancer*, 2012, 107, s. 429–434.
- 8 Yoshino, T. – Mizunuma, N. – Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol*, 2012, 13, s. 993–1001.
- 9 Mayer, R. J. – Van Cutsem, E. – Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*, 2015, 372, s. 1909–1919.
- 10 Ohtsu, A. – Yoshino, T. – Falcone, A., et al.: Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. ASCO 2016, abstrakt 3556.
- 11 Nishina, T. – Yoshino, T. – Shinozaki, E., et al.: Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). ASCO 2016, abstrakt 3557.
- 12 Dostupné z: [www.servier.cz/documents/SPC/Lonsurf\\_SPC.pdf](http://www.servier.cz/documents/SPC/Lonsurf_SPC.pdf), vyhledáno 4. 12. 2017
- 13 Dostupné z: [www.olecich.cz](http://www.olecich.cz)
- 14 Spurná, Z. – Bránčíková, D. – Katolická, J.: Kvalita života pacienta při podávání perorální onkologické léčby. *Onkologie*, 2009, 3, s. 101–105.

# Bezpečnostní profil ibrutinibu a idelalisibu

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Byrd, et al.**: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. ASCO 2017, abstrakt #7510.
- 2 **Puła, A. – Stawiski, K. – Braun, M., et al.**: Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. *Leuk Lymphoma*, 11. 9. 2017, s. 1–11.
- 3 **Salles, G. – Schuster, S. J. – de Vos, S., et al.**: Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. *Haematologica*, 2017, 102, s. e156–e159.
- 4 **PRAC concludes review of Zydelig and issues updated recommendations for use.** Dostupné z: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/2016/07/news\\_detail\\_002568.jsp&mid=WC0b01ac058004d5c1](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002568.jsp&mid=WC0b01ac058004d5c1), vyhledáno 6. 11. 2017.
- 5 **Jin, F. – Robeson, M. – Zhou, H., et al.**: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. *Cancer Chemother Pharmacol*, 2015, 76, s. 1133–1141.
- 6 **Jin, F. – Robeson, M. – Zhou, H., et al.**: The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. *J Clin Pharmacol*, 2015, 55, s. 944–952.

## Podkožní forma rituximabu – starý a přesto nový lék: co přináší z pohledu lékaře, zdravotní sestry a pacienta v běžné klinické praxi

doc. MUDr. Andrea Janíková, Ph.D. | Jana Charouzková  
Interní hematologická a onkologická klinika FN a LF MU, Brno

- 1 SPC Mabthera EMA 2017. Dostupné z: [www.ema.europa.eu/Mabthera-EMA/H/C/000165-IA/0136](http://www.ema.europa.eu/Mabthera-EMA/H/C/000165-IA/0136).
- 2 **Casulo, C. – Maragulia, J. – Zelenetz, A. D.**: Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. *Clin Lymphoma Myeloma Leuk*, 2013, 13, s. 106–111.
- 3 **Ghielmini, M. – Vitolo, U. – Kimby, E., et al.**: ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol*, 2013, 24, s. 561–576.
- 4 **Dreyling, M. – Thieblemont, C. – Gallamini, A., et al.**: ESMO Consensus conferences: guidelines on malignant lymphoma, part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. *Ann Oncol*, 2013, 24, s. 857–877.
- 5 **Shpilberg, O. – Jackisch, C.**: Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. *British J Cancer*, 2013, 109, s. 1556–1561.
- 6 **Salar, A. – Avivi, I. – Larouche, J., et al.**: Final results of the BP 22333 Study demonstrate noninferior pharmacokinetics and safety of subcutaneous versus intravenous rituximab as maintenance therapy in follicular lymphoma. *Hematol Oncol*, 2013, 31, suppl. 1, s. 195.
- 7 **Davies, A. – Merli, F. – Mihaljević, B., et al.**: Pharmacokinetics, safety, and overall response rate achieved with subcutaneous rituximab plus chemotherapy were comparable to those with intravenous administration in the first-line treatment of patients with follicular lymphoma: stage 1 results of the phase 3 SABRINA Study (BO22334). *Hematol Oncol*, 2013, 31, suppl. 1, abstrakt 194.

## Interakce léčiv prodlužujících QT interval

Mgr. Olga Svobodová

Oddělení klinické farmacie – Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno  
PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie – Lékárna, FN Ostrava  
doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU, Brno

- 1 **Goldenberg, I. – Zareba, W. – Moss, A.**: Long QT syndrom. *Curr Probl Cardiol*, 2008, 11, s. 629–694.
- 2 **Moss, A. – Robinson, J.**: Clinical features of the idiopathic long QT syndrome. *Circulation*, 1992, 85, s. 1140–1144.
- 3 **Jasiak, N. – Bostwick, J.**: Risk of QT/QTc prolongation among newer non-SSRI antidepressants. *Ann Pharmacother*, 2014, 48, s. 1620–1628.
- 4 **Roden, D. – George, A.**: Structure and functions of cardiac sodium and potassium channels. *Am J Physiol*, 1997, 273, s. 511–525.
- 5 **Hedly, P. – Jorgensen, P. – Schlamowitz, S., et al.**: The genetic basis of long QT and short QT syndromes: a mutation update. *Hum Mutat*, 2009, 30, s. 1486–1511.
- 6 **Yang, P. – Kanki, H. – Dorlet, B., et al.**: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. *Circulation*, 2002, 105, s. 1943–1948.
- 7 **Eijgelsheim, M. – Stricker, B. – van Noord, C.**: Drug- and non-drug-associated QT interval prolongation. *Br J Clin Pharmacol*, 2010, 1, s. 16–23.
- 8 Online dostupné z: <https://crediblemeds.org/new-drug-list/>, vyhledáno 28. 9. 2017.
- 9 **Roden, D. M.**: Pharmacogenetics of potassium channel blockers. *Card Electrophysiol Clin*, 2016, 8, s. 385–393.
- 10 **Briasoulis, A. – Agarwal, V. – Pierce, W. J.**: QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. *Cardiology*, 2011, 120, s. 103–110.
- 11 **Lee, K. – Jim, M. – Tang, S., et al.**: QT prolongation and torsades de pointes associated with clarithromycin. *Am J Med*, 1998, 4, s. 395–396.
- 12 **Owens, R., jr.**: QT prolongation with antimicrobial agents: understanding the significance. *Drugs*, 2004, 10, s. 1091–1124.
- 13 **Krausová, L. – Grim, J. – Pávek, P.**: Azolová antimykotika: mechanismy lékových interakcí. *Klin Farmakol Farm*, 2009, 2, s. 86–89.
- 14 **Glassman, A. – Bigger, J.**: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry*, 2001, 11, s. 1774–1782.
- 15 **Veiweg, W.**: New generation antipsychotic drugs and QTc interval prolongation. *Prim Care Companion J Clin Psychiatry*, 2003, 5, s. 205–215.
- 16 **Casazza, F. – Florista, F. – Rustici, A., et al.**: Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case. *G Ital Cardiol*, 1986, 12, s. 1058–1061.
- 17 Online dostupné z: <http://www.sukl.cz/riziko-prodlouzeni-intervalu-qt-u-pacientu-uzivajicich?highlightWords=citalopram>, vyhledáno 28. 9. 2017.
- 18 **Kuryshv, Y. – Brown, A. – Wang, L., et al.**: Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. *J Pharmacol Exp Ther*, 2000, s. 614–620.

## Fixní kombinace perindopril argininu s amlodipinem

prof. MUDr. Jiří Widimský, CSc. Jr. III. interní klinika – Centrum pro hypertenzi VFN a 1. LF UK, Praha

- 1 **Todd, P. A. – Fitton, A.**: Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. *Drugs*, 1991, 42, s. 90–114.
- 2 **Grundmann, M.**: Perindopril arginin – nová sůl inhibitoru ACE perindoprilu. *Farmakoterapie*, 2007, 3, s. 308–312.
- 3 **Abernethy, D. R.**: The pharmacokinetic profile of amlodipine. *Am Heart J*, 1989, 118, s. 1100–1103.
- 4 **Widimský, J. jr. – Cífková, R. – Špinar, J., et al.**: Doporučení diagnostických a léčebných postupů arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. *Cor et Vasa*, 2008, 1, s. K3–23.
- 5 **Brugts, J. J., et al.**: The consistency of the treatment effect of an angiotensin-converting enzyme-inhibitor-based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials comparing perindopril-indapamide vs. placebo. *Eur Heart J*, 2009, 30, s. 1385–1394.
- 6 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. Guidelines Committee. *J Hypertens*, 2007, 25, s. 1105–1187.
- 7 **Remuzzi, G. – Macia, M. – Ruggenenti, P.**: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. *J Am Soc Nephrol*, 2006, 17, suppl. 2, s. S90–S97.

- 8 Yusuf, S. – Sleight, P. – Pogue, J., et al.; for The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med*, 2000, 342, s. 145–153.
- 9 The EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*, 2003, 362, s. 782–788.
- 10 Bertrand, M. E.; on behalf of the EUROPA Executive Committee: Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients – analysis from the EUROPA study. Abstrakt / přednáška, Evropský kardiologický kongres, Mnichov, 2008.
- 11 Poulter, N. R.; for the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*, 2005, 366, s. 907–913.
- 12 The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators: Differential impact of blood pressure – lowering drugs on central aortic pressure and clinical outcomes. *Circulation*, 2006, 113, s. 1213–1225.
- 13 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 14 Bahl, V. K. – Jadhav, U. M. – Thacker, H. P.: Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practise. Results from the STRONG Prospective, Observational, Multicenter study. *Am J Cardiovasc Drugs*, 2009, 9, s. 135–142.
- 15 Ferrari, R.: Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. *Curr Med Res Opin*, 2008, 24, s. 3543–3557.
- 16 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 17 Fox, K., ústní prezentace, Evropský kardiologický kongres, Mnichov 2008.

## Inhibice systému RAAS perindopriem ve vztahu k dysfunkci endotelu: studie PERTINENT

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Fox, K. M.: The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (EUROPA). *Lancet*, 2003, 362, s. 782–788.
- 2 Braunwald, E. – Domanski, M. J. – Fowler, S. E., et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*, 2004, 351, s. 2058–2068.
- 3 Khalil, M. E. – Basher, A. W. – Brown, E. J. Jr., et al.: A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. *J Am Coll Cardiol*, 2001, 37, s. 1757–1764.
- 4 Remme, W. J. – Deckers, J. W. – Fox, K. M., et al. for the Europa Investigators: Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in Europa? *Cardiovasc Drugs Ther*, 2009, 23, s. 161–170.
- 5 Cecconi, C. – Fox, K. M. – Remme, W. J., et al.: ACE inhibition with perindopril and endothelial function. Results of a substudy of the Europa study: PERTINENT. *Cardiovasc Res*, 2007, 73, s. 237–246.
- 6 Ferrari, R. – Fox, K.: Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story. *Drugs*, 2009, 69, s. 265–277.

## Fixní kombinace candesartanu s amlodipinem

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Le, M. T. – Pugsley, M. K. – Vauquelin, G., et al.: Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. *Br J Pharmacol*, 2007, 151, s. 952–962.
- 2 Matsumori, A. – Ono, K. – Nishio, R., et al.: Amlodipine inhibits the production of cytokines induced by ouabain. *Cytokine*, 2000, 12, s. 294–297.
- 3 Matsumori, A. – Nishio, R. – Nose, Y.: Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. *Circ J*, 2010, 74, s. 567–571.
- 4 Dogrul, A. – Yesilyurt, O. – Deniz, G., et al.: Analgesic effects of amlodipine and its interaction with morphine and ketorolac-induced analgesia. *Gen Pharmacol*, 1997, 29, s. 839–845.
- 5 Ahrens, K. – Bramlage, P.: Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension. *Drugs Today*, 2010, 46, s. 339–350.
- 6 Takai, S. – Jin, D. – Shimamoto, T., et al.: Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. *Hypertens Res*, 2011, 34, s. 245–252.
- 7 Rakugi, H. – Ogihara, T. – Miyata, Y., et al.: Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*, 2012, 34, s. 838–848.
- 8 Yasuno, S. – Fujimoto, A. – Nakagawa, Y., et al.: Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. *Expert Rev Cardiovasc Ther*, 2012, 10, s. 577–583.
- 9 Maeda, A. – Tamura, K. – Kanaoka, T., et al.: Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY). *Clin Exp Hypertens*, 2012, 34, s. 249–257.
- 10 Yamaguchi, J. – Hagiwara, N. – Ogawa, H., et al.: Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). *Am J Cardiol*, 2010, 106, s. 819–824.
- 11 Koyanagi, R. – Hagiwara, N. – Yamaguchi, J., et al.: Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. *J Cardiol*, 2013, 62, s. 217–223.
- 12 Furuhashi, M. – Mita, T. – Moniwa, N., et al.: Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. *Hypertens Res*, 2015, 38, s. 252–259.
- 13 Sohn, I. S. – Kim, C. J. – Ahn, T., et al.: Efficacy and tolerability of combination therapy versus monotherapy with candesartan and/or amlodipine for dose finding in essential hypertension: a phase II multicenter, randomized, double-blind clinical trial. *Clin Ther*, 2017, 39, s. 1628–1638.

XXIV. kongres České internistické společnosti ČLS J. E. Purkyně, 29. 10. – 1. 11. 2017

## Intervence kardiovaskulárního rizika, proč vítězíme a selháváme

- 1 veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension results in patients with diastolic blood pressures averaging 115 through 129 mmHg. *JAMA*, 1967, 202, s. 1028–1034.
- 2 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA*, 1991, 265, s. 3255–3264.
- 3 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–9188.
- 4 Williamson, J. D. – Supiano, M. A. – Applegate, W. B., et al.; SPRINT Research Group: Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. *JAMA*, 2016, 315, s. 2673–2682.
- 5 Ettehad, D. – Emdin, C. A. – Kiran, A., et al.: Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*, 2016, 387, s. 957–967.
- 6 Franklin, S. S. – O'Brien, E. – Thijs, L., et al.: Masked hypertension: a phenomenon of measurement. *Hypertension*, 2015, 65, s. 16–20.
- 7 Bahiru, E. – de Cates, A. N. – Farr, M. R., et al.: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. *Cochrane Database Syst Rev*, 2017, 3, CD009868.
- 8 Cifková, R. – Skodová, Z. – Bruthans, J., et al.: Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. *J Hypertens*, 2010, 28, s. 2196–2203.
- 9 Mazzaglia, G. – Ambrosioni, E. – Alacqua, M., et al.: Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation*, 2009, 120, s. 1598–1605.
- 10 Böhm, M. – Schumacher, H. – Laufs, U., et al.: Effects of non-persistence with medication on outcomes in high-risk patients with cardiovascular disease. *Am Heart J*, 2013, 166, s. 306–314.
- 11 Itoh, H.: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study. Prezentováno na 2017 ESC Congress, Barcelona.
- 12 Hradec, J. – Bultas, J. – Kmínek, A., et al.: Jak se léčí statiny v České republice? *Cor Vasa*, 2011, 53, s. 527–534.
- 13 Khan, I.: Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor? Prezentováno na 2016 ESC Congress, Řím, poster 4990.
- 14 Chhatrivala, A. K. – Nicholls, S. J. – Wang, T. H., et al.: Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. *J Am Coll Cardiol*, 2009, 53, s. 1110–1115.
- 15 Bertrand, M. – Mourad, J. J.: Combining perindopril with a calcium channel blocker and a lipid lowering agent significantly decreases mortality: a subgroup analysis of EUROPA. *Circulation*, 2013, 128, supl., abstrakt A18906.
- 16 Chapman, R. H. – Benner, J. S. – Petrilla, A. A., et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. *Arch Intern Med*, 2005, 165, s. 1147–1152.
- 17 Kotseva, K. – De Bacquer, D. – De Backer, G., et al.; on behalf of The Euroaspirin Investigators. Lifestyle and risk factor management



- in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. *Eur J Prev Cardiol*, 2016, 23, s. 2007–2018.
- 18 van Halewijn, G. – Deckers, J. – Tay, H. Y., et al.: Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. *Int J Cardiol*, 2017, 232, s. 294–303.
- 19 Staessen, J. A. – Li, Y. – Thijs, L., et al.: Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. *Hypertens Res*, 2005, 28, s. 385–407.
- 20 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 21 Sever, P. – Dahlöf, B. – Poulter, N., et al.; ASCOT Steering Committee Members: Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. *Eur Heart J*, 2006, 27, s. 2982–2988.
- 22 Morris, L. S. – Schulz, R. M.: Patient compliance – an overview. *J Clin Pharm Ther*, 1992, 17, s. 283–295.
- 23 Lázaro, P. – Murga, N. – Aguilar, D., et al.; INERTIA Study Investigators: Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study. *Rev Esp Cardiol*, 2010, 63, s. 1428–1437.

## Perindopril erbumin prověřen klinickými studiemi

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Song, J. C. – White, C. M.: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. *Clin Pharmacokinet*, 2002, 41, s. 207–224.
- 2 Harder, S. – Thurmann, P. A. – Ungeth, W.: Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. *Br J Clin Pharmacol*, 1998, 45, s. 377–380.
- 3 Alfakih, K. – Hall, A. S.: Perindopril. *Expert Opin Pharmacother*, 2006, 7, s. 63–71.
- 4 Telejko, E.: Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. *Curr Med Res Opin*, 2007, 23, s. 953–960.
- 5 Dietz, R. – Feilner, K. – Gerst, F., et al.: Drug stability testing. Classification of countries according to climatic zone. *Drugs made in Germany*, 1993, 36, s. 99–103.

## Porovnání klinického efektu Warfarinu PMCS vůči Warfarinu Orion

MUDr. Petr Magrot OKB Lab, a. s., Ústí nad Labem Leona Hrdličková, DiS. SVZŠ, Ústí nad Labem

- 1 Gao, D. – Maurin, M. B.: Physical chemical stability of warfarin sodium. *AAPS PharmSci*, 2001, 3, s. 1–8.
- 2 Souhrn údajů o přípravku Warfarin PMCS 2 mg, Warfarin PMCS 5 mg tablety, sp. zn. suklS 218737/2016.
- 3 Souhrn údajů o přípravku Warfarin Orion 3 mg, Warfarin Orion 5 mg tablety, sp. zn. suklS 221027/2016.
- 4 Pecka, M.: *Laboratorní hematologie v přehledu, Fyziologie a patofyziologie hemostazy*. Český Těšín, Finidr, 2004, s. 214–216.

## Léčba bolesti v těhotenství s ohledem na změnu farmakokinetiky těhotných

PharmDr. Eliška Vaculíková Nemocniční lékárna, Pracoviště klinického farmaceuta Nemocnice s poliklinikou Havířov Mgr. Olga Svobodová Oddělení klinické farmacie – Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno MUDr. Jan Malaník Gynekologicko-porodní oddělení Slezské nemocnice Opava

- 1 Schaefer, Ch. – Peters, P. – Miller, R. K.: *Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment*. Elsevier, 2015, s. 11.
- 2 International Association for the Study of Pain, online. Dostupné z: <http://www.iasp-pain.org/Taxonomy>, vyhledáno 5. 11. 2015.
- 3 Medical Dictionary for the Health Professions and Nursing. Dostupné z: <http://medical-dictionary.thefreedictionary.com/pain+threshold>, vyhledáno 5. 11. 2015.
- 4 Loebstein, R. – Lalkin, A. – Koren, G.: Pharmacokinetic changes during pregnancy and their clinical relevance. *Clin Pharmacokinet*, 1997, 33, s. 328–343.
- 5 Biernetová Vašků, J.: Patofyziologie fetoplacentární jednotky [prezentace PowerPoint]. Brno, projekt: CZ.1.07/2.2.00/28.0041. Dostupné z [https://is.muni.cz/el/1411/jaro2014/BVPF0422c/um/NT-Patofyziologie\\_fetoplacentarni\\_jednotky.pdf](https://is.muni.cz/el/1411/jaro2014/BVPF0422c/um/NT-Patofyziologie_fetoplacentarni_jednotky.pdf), vyhledáno 5. 9. 2017.
- 6 Kirchnerová, M. – Suchánková, H. – Mrozek, Z.: Anestezie u operací v těhotenství. *Klinická farmakologie a farmacie*, 2014, 28, s. 62–64.
- 7 Constantine, M. M.: Physiologic and pharmacokinetic changes in pregnancy. *Front Pharmacol*, 2014, 5, s. 65.
- 8 Davison, J. M. – Dunlop, W.: Changes in renal hemodynamics and tubular function induced by normal human pregnancy. *Semin Nephrol*, 1984, 4, s. 198.
- 9 Pacheco, L. – Costantine, M. M. – Hankins, G. D. V.: Physiologic changes during pregnancy. In: Mattison D. R. (ed.): *Clinical Pharmacology During Pregnancy*. San Diego, Academic Press, 2013, s. 5–14.
- 10 Barron, W. M. – Lindheimer, M. D.: Renal sodium and water handling in pregnancy. *Obstet Gynecol Annu*, 1984, 13, s. 35–69.
- 11 Rubler, S. – Damani, P. M. – Pinto, E. R.: Cardiac size and performance during pregnancy estimated with echocardiography. *Am J Cardiol*, 1977, 40, s. 534–540.
- 12 Clark, S. L. – Cotton, D. B. – Lee, W., et al.: Central hemodynamic assessment of normal term pregnancy. *Am J Obstet Gynecol*, 1989, 161, s. 1439–1442.
- 13 Capeless, E. L. – Clapp, J. F.: When do cardiovascular parameters return to their preconception values? *Am J Obstet Gynecol*, 1991, 165, s. 883–886.
- 14 Robson, S. C. – Hunter, S. – Boys, R. J., et al.: Serial study of factors influencing changes in cardiac output during human pregnancy. *Am J Physiol*, 1989, 256, s. 1060–1065.
- 15 Hytten, F. E. – Paintin, D. B.: Increase in plasma volume during normal pregnancy. *J Obstet Gynaecol Br Emp*, 1963, 70, s. 402–407.
- 16 Taylor, M.: An experimental study of the influence of the endocrine system on the nasal respiratory mucosa. *J Laryngol Otol*, 1961, 75, s. 972–977.
- 17 Patofyziologie výměny dýchacích plynů v plicích. Patofyziologie řízení dýchání. Dostupné z: [www.med.muni.cz/patfyz/powerpnt/0607/dych\\_systPP2006.ppt](http://www.med.muni.cz/patfyz/powerpnt/0607/dych_systPP2006.ppt), prezentace, 18. 10. 2006, vyhledáno 31. 1. 2017.
- 18 Elkus, R. – Popovich, J. Jr.: Respiratory physiology in pregnancy. *Clin Chest Med*, 1992, 13, s. 555–565.
- 19 Tsai, C. H. – de Leeuw, N. K.: Changes in 2,3-diphosphoglycerate during pregnancy and puerperium in normal women and in beta-thalassemia heterozygous women. *Am J Obstet Gynecol*, 1982, 142, s. 520–523.
- 20 Cappel, M. S. – Garcia, A.: Gastric and duodenal ulcers during pregnancy. *Gastroenterol Clin North Am*, 1998, 27, s. 169–195.
- 21 Parry, E. – Shields, R. – Turnbull, A. C.: Transit time in the small intestine in pregnancy. *J Obstet Gynaecol Br Commonw*, 1970, 77, s. 900–901.
- 22 Dawes, M. – Chowienczyk, P. J.: Drugs in pregnancy. Pharmacokinetics in pregnancy. *Best Pract Res Clin Obstet Gynaecol*, 2001, 15, s. 819–826.
- 23 Clements, J. A. – Heading, R. C. – Nimmo, W. S., et al.: Kinetics of acetaminophen absorption and gastric emptying in man. *Clin Pharmacol Ther*, 1978, 24, s. 420–431.
- 24 Little, B. B.: Pharmacokinetics during pregnancy: evidence-base maternal dose formulation. *Obstet Gynecol*, 1999, 93, s. 858–868.
- 25 de Hann, G. J. – Edelbroek, P. – Segers, J., et al.: Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. *Neurology*, 2004, 63, s. 571–573.
- 26 Paralen 500. SÚKL, 2010, dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0155148&tab=texts>, vyhledáno 10. 8. 2017.
- 27 Roberts, I. – Robinson, M. J. – Mughal, M. Z., et al.: Paracetamol metabolites in the neonate following maternal overdose. *Br J Clin Pharmacol*, 1984, 18, s. 201–206.
- 28 Nosková, P.: Léčba bolesti během gravidity a laktace. *Medicina pro praxi*, 2011, 8, s. 370–373.
- 29 Novalgin. SÚKL, 2010, dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0055823&tab=texts>, vyhledáno 10. 8. 2017.
- 30 Fitzpatrick, F. A.: Cyclooxygenase enzymes: regulation and function. *Curr Pharm Des*, 2004, 10, s. 577–588.
- 31 Werler, M. M. – Mitchell, C. A. – Honein, M. A.: Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? National Birth Defects Prevention Study. *Am J Med Genetics*, 2009, 149A, s. 1399–1406.
- 32 Gastroschisis. Velký lékařský slovník, Maxdorf, 1998–2017, dostupné z: <http://lekarske.slovníky.cz/lexikon-pojem/gastroschisis>, vyhledáno 10. 3. 2017.
- 33 Østensen, M. – Förger, F.: Management of RA medications in pregnant patients. *Nat Rev Rheumatol*, 2009, 5, s. 382–390.
- 34 Celebrex. SÚKL, 2010, dostupné z: <http://www.sukl.cz/modules/medication/detail.php?kod=0085026>, vyhledáno 25. 8. 2017.
- 35 Arcoxia. SÚKL, 2010, dostupné z: <http://www.sukl.cz/modules/medication/detail.php?kod=0099969>, vyhledáno 25. 8. 2017.
- 36 Kassim, Z. – Greenough, A.: Neonatal abstinence syndrom: Identification and management. *Current Pediatrics*, 2006, 16, s. 172–175.
- 37 Claahsen-van der Grinten, H. L. – Verbruggen, I. – van den Berg, P. P., et al.: Different pharmacokinetics of tramadol in mother treated for labour pain and in their neonates. *Eur J Clin Pharmacol*, 2005, 61, s. 523–529.
- 38 Reiff-Eldridge, R. – Heffner, C. R. – Ephross, S. A., et al.: Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. *Am J Obstet Gynecol*, 2000, 182, s. 159–163.

# Tapentadol v léčbě chronické nenádorové bolesti – kazuistika

MUDr. Lenka Klimešová ARIM, Nemocnice Milosrdných bratří, Brno

- 1 **Baron, R. – Likar, R. – Martin-Mola, E., et al.**: Effectiveness of tapentadol prolonged release compared with oxycodone/naloxone for management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. *Pain Practice*, 2016, 16, s. 580–599.
- 2 **Baron, R. – Jansen, J.-P. – Binder, A., et al.**: Tolerability, safety, and quality of life with tapentadol prolonged release compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. *Pain Practice*, 2016, 16, s. 600–619.
- 3 **Buynak, R. – Shapiro, D. Y. – Okamoto, A., et al.**: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. *Expert Opin Pharmacother*, 2010, 11, s. 1787–1804.
- 4 **Nicholson, B.**: Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. *Pain Pract*, 2009, 9, s. 71–81.
- 5 **Freyhagen, R. – Baron, R. – Gockel, U., et al.**: painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin*, 2006, 22, s. 1911–1920.
- 6 **Lange, B. – Kuperwasser, B. – Okamoto, A., et al.**: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. *Adv Ther*, 2010, 27, s. 381–399.
- 7 **Sánchez del Aguila, M. J. – Schenk, M. – Kern K.-U. – Drost, T., et al.**: Practical considerations for the use of tapentadol prolonged release for management of severe chronic pain. *Clin Ther*, 2015, 7, s. 94–113.
- 8 **Schwartz, S. – Etropolski, M. – Shapiro, D. Y., et al.**: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin*, 2011, 27, s. 151–162.

# Nová možnost léčby revmatoidní artritidy – Olumiant

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 **Genovese, M. C., et al.**: Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med*, 2016, 374, s. 1243–1252.
- 2 **Fleischman, R., et al.**: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Rheumatol*, 2017, 69, 3, s. 506–517.
- 3 **Dougados, M. – van der Heijde, D. – Chen, Y.-C., et al.**: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis*, 2017, 76, s. 88–95.
- 4 **Van der Heijde, D. – Dougados, M. – Chen, Y.-C., et al.**: THU0168 baricitinib inhibits radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis (RA) and an inadequate response to csDMARDs. *Ann Rheum Dis*, 2016, 75, s. 244–245.
- 5 **Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.**: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- 6 **Závada, J.**: Komentář ke studii. *Farmakoterapie*, 2017, 3, s. 440–442.
- 7 **Šenolt, L. – Mann, H. – Závada, J., et al.**: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy. *Čes Revmatol*, 2017, 25, s. 8–24.
- 8 **Schwartz, D., et al.**: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*, 2016, 12, s. 25–36.
- 9 **Norman, P.**: Selective JAK inhibitors in development for rheumatoid arthritis. *Expert Opin Investig Drugs*, 2014, 23, s. 1067–1073.

# Secukinumab v léčbě pacientky se závažným průběhem psoriázy a psoriatické artritidy – kazuistika

MUDr. Martina Kojanová, Ph.D. | MUDr. Jorga Fialová  
Dermatovenerologická klinika 1. LF UK a VFN, Praha

MUDr. Liliana Šedová Revmatologický ústav, Praha, Revmatologická klinika 1. LF UK, Praha

- 1 **Kojanová, M. – Fialová, J. – Cetkovská, P., et al.**: Analýza pacientů se středně těžkou až těžkou psoriázou před zahájením biologické léčby v České republice – údaje z registru BIOREP 2005–2016. *Čs Derm*, 2016, 5, s. 223–232.
- 2 Dostupné z: <http://www.sukl.cz/modules/medication/search.php>, vyhledáno 18. 11. 2017.
- 3 Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0167600&tab=prices>, vyhledáno 18. 11. 2017.
- 4 Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0210317&tab=prices>, vyhledáno 18. 11. 2017.
- 5 Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0209310&tab=prices>, vyhledáno 18. 11. 2017.
- 6 Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0210310&tab=prices>, vyhledáno 18. 11. 2017.
- 7 Dostupné z: <http://www.revmatologicka-spolecnost.cz/doporucene-postupy-crs>, vyhledáno 18. 11. 2017.
- 8 **Costa, L. – Perricone, C. – Chimenti, M. S., et al.**: Switching between biological treatments in psoriatic arthritis: a review of the evidence. *Drugs R D*, 2017, 4, s. 509–522.
- 9 **Merola, J. F. – Lockshin, B. – Modry, E. A.**: Switching biologics in the treatment of psoriatic arthritis. *Semin Arthritis Rheum*, 2017, 1, s. 29–37.
- 10 **Abrouk, M. – Gandy, J. – Nakamura, M., et al.**: Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature. *Skin Therapy Lett*, 2017, 4, s. 1–6.
- 11 **McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.**: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, 9999, s. 1137–1146.
- 12 **Behrens, F. – Cañete, J. D. – Olivieri, I., et al.**: Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. *Rheumatology (Oxford)*, 2015, 5, s. 915–926.
- 13 **Kerdel, F. – Zaiac, M.**: An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. *Dermatol Ther*, 2015, 6, s. 390–403.
- 14 **Mrowietz, U. – de Jong, E. M. – Kragballe, K., et al.**: A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. *J Eur Acad Dermatol Venereol*, 2014, 28, s. 438–453.
- 15 **Ormerod, A. D.**: Switching biologics for psoriasis. *Br J Dermatol*, 2010, 163, s. 667–669.
- 16 **Brezinski, E. A. – Armstrong, A. W.**: Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. *Semin Cutan Med Surg*, 2014, 33, s. 91–97.
- 17 **Strober, B. E. – Bissonnette, R. – Fiorentino, D., et al.**: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). *J Am Acad Dermatol*, 2016, 5, s. 851–861.
- 18 **Yamauchi, P. S. – Bissonnette, R. – Teixeira, H. D., et al.**: Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. *J Am Acad Dermatol*, 2016, 3, s. 612–618.
- 19 **Menter, A. – Papp, K. A. – Gooderham, M., et al.**: Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *J Eur Acad Dermatol Venereol*, 2016, 7, s. 1148–1158.
- 20 **Gniadecki, R. – Bang, B. – Bryld, L. E., et al.**: Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. *Br J Dermatol*, 2015, 172, s. 244–252.
- 21 **Griffiths, C. E. – Strober, B. E. – van de Kerkhof, P., et al.**: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med*, 2010, 362, s. 118–128.
- 22 **Blauvelt, A. – Reich, K. – Tsai, T. F., et al.**: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. *J Am Acad Dermatol*, 2017, 1, s. 60–69.
- 23 **Thaçi, D. – Blauvelt, A. – Reich, K., et al.**: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*, 2015, 3, s. 400–409.
- 24 **Pelechas, E. – Memi, T. – Voulgari, P. V., et al.**: A case of recalcitrant psoriatic arthritis to TNF inhibitors improved after administration of secukinumab, an IL-17A inhibitor. *Rheumatol Ther*, 2017, 2, s. 509–513.

# Fixní kombinace azelastinu a fluticason propionátu – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Bousquet, J. – Bachert, C. – Bernstein, J., et al.**: Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. *Expert Opin Pharmacother*, 2015, 16, s. 913–928.
- 2 **Derendorf, H. – Munzel, U. – Petzold, U., et al.**: Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. *Br J Clin Pharmacol*, 2012, 74, s. 125–133.

- 3 Hampel, F. C. – Ratner, P. H. – Van, B. J., et al.: Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. *Ann Allergy Asthma Immunol*, 2010, 105, s. 168–173.
- 4 Carr, W. – Bernstein, J. – Lieberman, P., et al.: A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol*, 2012, 129, s. 1282–1289.
- 5 Prenner, B. M.: A review of the clinical efficacy and safety of MP-29-Flu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. *J Asthma Allergy*, 2016, 9, s. 135–143.
- 6 Klimek, L. – Bousquet, J. – Price, D.: Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. *Expert Opin Drug Saf*, 2016, 15, s. 117–129.

## Současný pohled na léčbu idiopatické plicní fibrózy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Meltzer, E. B. – Noble, P. W.: Idiopathic pulmonary fibrosis. *Orphanet J Rare Dis*, 2008, 3, s. 8.
- 2 Raghu, G. – Rochwerg, B. – Zhang, Y., et al.: An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: an update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*, 2015, 192, s. e3–19.
- 3 Fleetwood, K. – McCool, R. – Glanville, J., et al.: Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments. *J Manag Care Spec Pharm*, 2017, 23, suppl., s. S5–S16.

## Fosfomycin trometamol – od laboratorního ověření účinnosti k urologické praxi

MUDr. Miroslav Louda, Ph.D. Urologická klinika FN a LF UK, Hradec Králové

MUDr. Miroslav Fajfr, Ph.D. Ústav klinické mikrobiologie, FN Hradec Králové

- 1 Cassir, N. – Rolain, J. M. – Brouqui, P.: A new strategy to fight antimicrobial resistance: the revival of old antibiotics. *Front Microbiol*, 2014, 20, s. 551, doi: 10.3389/fmicb.2014.00551.
- 2 Raz, R.: Fosfomycin: an old-new antibiotic. *Clin Mikrob Infekt*, 2012, 18, s. 4–7.
- 3 Frimodt-Møller, N.: Chapter 73: Fosfomycin. In: *Kucers' The Use of Antibiotics*. 6. vydání, ASM Press, 2010.
- 4 Fajfr, M. – Louda, M. – Paterová, P., et al.: The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. *BMC Urol*, 2017, 17, s. 33, doi: 10.1186/s12894-017-0222-6.
- 5 Fajfr, M. – Louda, M. – Paterová, P., et al.: Fosfomycin trometamol – staronové antibiotikum v urologické praxi. *Urol Pro Praxi*, 2015, 16, s. 148–150.
- 6 SÚKL, Souhrn údajů o přípravku Rapidnorm 3000 mg. Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0179093&tab=texts>, vyhledáno 10. 10. 2017.
- 7 Schmiemann, G. – Gágyor, I. – Hummers-Pradier, E., et al.: Resistance profiles of urinary tract infections in general practice – an observation study. *BMC Urology*, 2012, 12, s. 33, doi: 10.1186/1471-2490-12-33.
- 8 Neuner, E. A. – Sekeres, J. – Hall, G. S., et al.: Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. *Antimicrob Agents Chemother*, 2012, 56, s. 5744–5748.
- 9 Kaase, M. – Szabados, F. – Anders, A., et al.: Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. *J Clin Microbiol*, 2014, 52, s. 1893–1897.

## Farmakologická léčba benigní hyperplazie v současnosti

MUDr. Jiří Klečka, Ph.D., MBA

Urocentrum Plzeň a Urologická klinika FN Královské Vinohrady a 3. LF UK, Praha

- 1 American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). Dostupné z: [www.auanet.org](http://www.auanet.org) (updated 2006).
- 2 Welch, G. – Weinger, K. – Barry, M. J.: Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study. *Urology*, 2002, 59, s. 245–250.
- 3 Sung, J. C. – Cuttis, L. H. – Schulman, K. A., et al.: Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. *J Urol*, 2006, 175, s. 1023–1027.
- 4 McVary, K. T.: A review of combination therapy in patients with benign prostatic hyperplasia. *Clin Ther*, 2007, 29, s. 387–398.
- 5 Berry, S. J. – Coffey, D. S. – Walsh, P. C., et al.: The development of human prostatic hyperplasia with age. *J Urol*, 1984, 132, s. 474–479.
- 6 McVary, K. T.: Sexual function and alpha-blockers. *Rev Urol*, 2005, 7, s. 53–511.
- 7 Roehrborn, C. G.; ALFUS Study Group: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia; a randomized, placebo-controlled trial. *Urology*, 2001, 58, s. 953–959.
- 8 McConnell, J. D. – Bruskeiwitz, R. – Walsh, P., et al.; Finasteride Long-Term Efficacy and Safety Study Group: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. *N Engl J Med*, 1998, 338, s. 557–563.
- 9 Stief, C. G. – Porst, H. – Neuser, D., et al.: A randomized placebo controlled study to assess the efficacy of twice daily Vardenafil in the treatment of LUTS secondary to BPH. *Eur Urol*, 2008, 53, s. 1236–1244.
- 10 Kaplan, S. A. – Roehrborn, C. G. – Rovner, E. S., et al.: Tolerodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA*, 2006, 296, s. 2319–2328.
- 11 Marks, L. S. – Gittelman, M. C. – Hill, L. A., et al.: Rapid efficacy of the highly selective  $\alpha_{1A}$ -adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. *J Urol*, 2009, 181, suppl. 1, s. 694–695.
- 12 Roehrborn, C. G. – Schwinn, D. A.: Alpha<sub>1</sub>-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. *J Urol*, 2004, 171, s. 1029–1035.
- 13 Roehrborn, C. G. – Siami, P. – Barkin, J., et al.: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. *Eur Urol*, 2010, 57, s. 123–131.

## Význam perorální léčby roztroušené sklerózy v první linii

prof. MUDr. Jan Mareš, Ph.D. Neurologická klinika LF UP a FN Olomouc

- 1 Dufek, M.: Léčba roztroušené sklerózy v České republice – možnosti a realita. *Neural Praxi*, 2014, 15, s. 31–35.
- 2 Havrdová, E., et al.: *Neuroimmunologie*. Praha, Maxdorf, 2001.
- 3 Havrdová, E.: Vývoj nových léků v oblasti RS – změnila se prognóza pacienta? *Neural Praxi*, 2011, 12, s. 170–174.
- 4 Krasulová, E. – Havrdová, E.: Léčba relaps-remitentní roztroušené sklerózy mozkomíšni. *Neural Praxi*, 2008, 4, s. 202–206.
- 5 Krasulová, E.: Teriflunomid v léčbě roztroušené sklerózy. *Acta Medica*, 2015, 1, s. 70–72.
- 6 Krasulová, E.: Teriflunomid. *Farmakoterapie*, 2014, 10, s. 697–702.
- 7 Mareš, J.: Moderní léčba roztroušené sklerózy. *Sanquis*, 2008, 59, s. 95.
- 8 Matejčíková, Z.: Aubagio (teriflunomid) jako jedna z možností léčby u mužů s roztroušenou sklerózou. *Neural Praxi*, 2017, 18, s. 49–53.
- 9 Meluzinová, E. – Bortlík, M.: Dimethyl-fumarát v léčbě relabující-remitující formy roztroušené sklerózy. *Klin Farmakol Farm*, 2015, 29, s. 119–122.
- 10 Kuhle, J. – Pohl, C. – Mehling, M., et al.: Lack of association between antimyelin antibodies and progression to multiple sclerosis. *N Engl J Med*, 2007, 356, s. 371–378.
- 11 Saiz, A. – Carreras, E. – Berenguer, J., et al.: MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. *Neurology*, 2001, 56, s. 1084–1089.
- 12 Zapletalová, O.: Teriflunomid – nový perorální imunomodulační lék první linie v léčbě roztroušené sklerózy. *Remedia*, 2015, 25, s. 1–4.
- 13 Zapletalová, O.: Teriflunomid. *Remedia*, 2014, 24, s. 336–341.
- 14 Zapletalová, O.: Teriflunomid – nový perorální imunomodulační lék první linie v léčbě roztroušené sklerózy. *Remedia*, 2015, 25, s. 1–4.